Abivax Announces a Board Restructure
Abivax SA (Euronext Paris & Nasdaq: ABVX), a forward-thinking biotechnology company, has shared important news regarding its board of directors. The company, which focuses on developing therapies that leverage the body's natural mechanisms to fight inflammatory diseases, announced the departure of Dr. Philippe Pouletty from his director position, effective December 31, 2024. This change comes as Dr. Pouletty has taken on new responsibilities as Chairman and acting CEO of a listed biotechnology firm specializing in plastics recycling.
Dr. Philippe Pouletty’s Legacy
Dr. Pouletty has played an instrumental role in the formation and growth of Abivax since its inception in 2013. Serving as Chairman until 2022, his leadership has propelled the company into the spotlight of innovative therapeutic development, particularly with the lead drug candidate, obefazimod. His dedication to Abivax has been unwavering, and he expressed great pride in having contributed to its journey thus far.
Comments from Dr. Pouletty
Reflecting on his time with the company, Dr. Pouletty stated, "It is a great pride for me and Truffle Capital to have founded Abivax and to have contributed to the development of obefazimod for over a decade. I am convinced that Abivax, led by a strong CEO, management team, and board of directors, has the potential to help hundreds of thousands of patients suffering from severe inflammatory diseases." He looks forward to Truffle Capital's continued support as a major shareholder through crucial upcoming milestones, including the anticipated Phase 3 ABTECT data readout in the near future.
New Directions for Abivax
Sylvie Grégoire, PharmD, the current chair of Abivax's board, has expressed gratitude for Dr. Pouletty's substantial contributions to the organization. She noted, "As a founder and former chairman, Dr. Pouletty has played a pivotal role in guiding the Company to the forefront of therapeutic innovation."
Search for New Board Members
Looking forward, the board is committed to filling the position left by Dr. Pouletty with a strong candidate who can further advance Abivax's late-stage pipeline in inflammatory bowel disease (IBD). The company is eager to continue driving innovation within their therapeutic landscapes, especially as obefazimod is currently in Phase 3 clinical trials for ulcerative colitis.
About Abivax and Its Innovations
Abivax is recognized for its role in the biotechnology sector, particularly in the development of treatments targeting chronic inflammatory diseases. With a focus on therapies that harness natural mechanisms for inflammation modulation, Abivax is poised to make significant advancements in the field. As it stands, obefazimod (ABX464) is a leading candidate in clinical trials aimed at addressing the needs of patients with moderately to severely active ulcerative colitis. The company remains dedicated to its mission, with operations in both France and the United States, and encourages following their updates on professional networks.
*****
Contact Information:
Patrick Malloy
SVP, Investor Relations
Email: patrick.malloy@abivax.com
Phone: +1 847 987 4878
Frequently Asked Questions
What prompted Dr. Philippe Pouletty's departure from the board?
Dr. Pouletty resigned to focus on his new role as Chairman and acting CEO of another biotechnology company.
How long has Dr. Pouletty been involved with Abivax?
Dr. Pouletty has been involved since the company was founded in December 2013.
What is the main product candidate of Abivax?
Abivax's lead drug candidate, obefazimod (ABX464), is being developed for the treatment of ulcerative colitis.
What does the future hold for Abivax’s board structure?
The board is actively searching for a strong candidate to fill the vacancy left by Dr. Pouletty to continue driving the company’s goals forward.
How does Abivax aim to support patients with chronic diseases?
Abivax aims to develop treatments that utilize the body’s natural regulatory mechanisms to effectively address chronic inflammatory diseases.
